Recipharm named Vikas Gupta as President of its recently renamed biologics business arm. Gupta joins ReciBioPharm from Repligen, where he was Vice President & General Manager, Gene Therapy and Downstream Bioprocessing. The appointment comes as Recipharm officially renames its biologics business division after the acquisitions of Arranta Bio, GenIbet and Vibalogics.
1st Jan change | Capi. | |
---|---|---|
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |